This medication has proven to be a game-changer, demonstrating a substantial reduction in the five-year risk of recurrent cancer by an impressive 73% ... Nov 14
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%... Dec 21
Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose ... Dec 19
Option would extend dosing to four weeks in non-small cell lung and bladder cancer reducing medical visits by half ... Aug 20
AstraZeneca comes up with ground breaking data on lungs cancer... Mar 02
Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study Phase II INSIGHT 2 study now open for enrollment for ... Sep 12
Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in ... Sep 11
-Advertisements-
Monday, May 13, 2024
.jpeg)
